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Background. Loss of visual function diﬀers between immune-mediated optic neuropathies and is related to axonal loss in the
optic nerve. This study investigated the diagnostic and prognostic value of a biomarker for neurodegeneration, the neurofilament
heavy chain (NfH) in three immune-mediated optic neuropathies. Methods. A prospective, longitudinal study including patients
with optic neuritis due to multiple sclerosis (MSON, n = 20), chronic relapsing inflammatory optic neuritis (CRION, n = 19),
neuromyelitis optica (NMO, n = 9), and healthy controls (n = 28). Serum NfH-SMI35 levels were quantified by ELISA. Findings.
Serum NfH-SMI35 levels were highest in patients with NMO (mean 0.79±1.51 ng/mL) compared to patients with CRION (0.13±
0.16 ng/mL, P = 0.007), MSON (0.09± 0.09, P = 0.008), and healthy controls (0.01± 0.02 ng/mL, P = 0.001). High serum NfH-
SMI35 levels were related to poor visual outcome. Conclusions. Blood NfH-SMI35 levels are of moderate diagnostic and more
important prognostic value in immune-mediated optic neuropathies. We speculate that longitudinal blood NfH levels may help
to identify particular disabling events in relapsing conditions.
1. Introduction
An established biomarker for neurodegeneration are body
fluid neurofilament (Nf) levels [1–3]. Damage to human
central nervous system initiates a proteolytic cascade which
causes release of Nf from neurons and axons into the
extracellular fluid (ECF) [4]. Next, Nf move from the ECF
into the cerebrospinal fluid (CSF) from where they diﬀuse
into the systemic blood circulation. Therefore quantification
of Nf from either body fluid permits to estimate the amount
of neuroaxonal damage caused.
Cerebrospinal Fluid levels (CSF) of the Nf heavy chain
(NfH SMI35) were higher in patients with a Clinically
Isolated Syndrome including optic neuritis compared to
control subjects and to correlate with disease activity [5] A
Japanese study found the CSF NfHSMI35 concentration to
be higher in patients with NMO (mean 0.75 ng) compared
with the levels found in multiple sclerosis (MS, 0.09 ng/mL)
[6]. This data is consistent with a European study [7]. Using
a diﬀerent analytical method, pNfH levels were however
found to be comparable between patients with MS, NMO,
spinal cord infarction, and controls [8]. Notably, CSF pNfH
levels in this paper were also virtually absent from other
conditions with known extensive axonal damage and high
CSF NfHSMI35 levels suggesting a preanalytical or analytical
problem.
Blood Nf heavy chain (NfH) levels have been shown to be
elevated in patients with acute optic neuritis compared with
control subjects, and its level correlates inversely with visual
loss and the retinal nerve fibre thickness as assessed by retinal
optical coherence tomography (OCT) [9–11].
The clinical spectrum of autoimmune ON includes
Neuromyelitis Optica (NMO, Devic disease) and disease
occurring as part of an Aquaporin 4 antibody spectrum
(AQP4+), as well as Chronic Relapsing Inflammatory Optic
Neuropathy (CRION) [12, 13]. Optic neuritis occurring as
part of a multiple sclerosis spectrum (MSON)may present in
exactly the same way as that occurring as part of an AQP4+
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Table 1: Patient characteristics. The median (numbers) are pre-
sented.
CTRL MSON CRION NMO
N 20 28 19 9
Age 34 33 45 29
Followup n/a 5 65 67
VA baseline ≥1 0.1 0.008 0.01
VA outcome n/a 0.67 0.1 0.33
NfH (ng/mL) 0.00 0.055 0.07 0.12
F: female, M: male, VA: visual acuity, CTRL: control subjects, MSON:
multiple sclerosis optic neuritis, CRION: chronic relapsing isolated optic
neuropathy, NMO: neuromyelitis optica.
spectrum, whereas the treatment required for the first is very
diﬀerent to that required for the second [14]. The timing of
steroid treatment in optic neuritis caused by NMO and other
immune mediated optic neuropathies has been shown to be
critical in the prevention of permanent retinal nerve fibre loss
[15]. It is therefore of great use to identify cases of NMO from
other immune mediated optic neuropathies.
This study investigated the diagnostic and prognostic
value of plasma NfHSMI35 levels for diﬀerentiating NMO
from non-NMO optic neuritis on the hypothesis that axonal
loss in the optic nerve may be greater in the former.
2. Methods
2.1. Patients. Consecutive patients presenting with optic
neuritis (ON) and healthy control subjects were recruited
from The National Hospital of Neurology and Neurosurgery,
Queen Square, St. Thomas’ Hospital, and Moorfields Eye
Hospital, all based in London, UK. Patients were classified
into ON in the context of multiple sclerosis (MSON),
CRION, and NMO as described [16, 17]. In all patients a
diagnosis of optic neuritis was made clinically as described
[9]. We exclude patients in whom transient visual distur-
bances were due to Uhthoﬀ ’s phenomenon.
Serum samples were obtained by antecubital venopunc-
ture. All samples were collected and processed at room
temperature in polypropylene tubes within two hours after
venopuncture. Samples were spun at 2000 g for 10 minutes.
Samples were then stored in 500 uL aliquots in 1.5mL
Eppendorf tubes at −80◦C.
Visual acuity (VA) was measured on Snellen charts and
expressed in decimals. In cases of unilateral ON, the VA of
the aﬀected eye was recorded. In the case of bilateral ON, the
VA of the worse eye was recorded. Poor vision was defined as
hand movements only (6/60). National ethics permission for
the study was sought by and granted to the Department of
Neurology, Walton centre for Neurology and Neurosurgery,
Liverpool (L9 7LJ), and informed consent was obtained from
all subjects.
2.2. Neurofilament Test. Serum neurofilament levels
(NfHSMI35) were measured in duplicates with the analyst
being blinded to all other information using a standard in-
house ELISA [18]. In brief, the mouse monoclonal antibody
SMI35 was purchased from Sternberger Monoclonals
Inc. This antibody is now available through Covance
Research Products (Berkeley, CA, USA). Both, the secondary
and tertiary antibodies were polyclonal and purchased
from (Sigma, St. Louis, MO, USA; N 4142) and (DAKO,
Copenhagen, Denmark, horseradish peroxidase (HRP)-
labeled swine polyclonal anti-rabbit IgG). Adhering to a
previously proposed nomenclature, we indicate the captured
antibodies used for NfH quantification in superscript
(NfHSMI35 for SMI35). The detection limit for the NfHSMI35
assay is 0.01 ng/mL. Serum NfHSMI35 levels above the highest
value observed in the control group were classified as
pathological.
2.3. Aquaporin 4 Test. Serum aquaporin 4 antibodies
(AQP4) were tested at the Mayo Clinic laboratories by
indirect immunofluorescence as described [19].
2.4. Statistical Analysis. All statistical analyses were per-
formed using SAS (V9.1). For comparison of two variables
the nonparametric Wilcoxon two-sample test was used.
General linear model were used for comparison of more
than two variables. Proportions of patients were compared
using Fisher’s exact test. A P value of 0.05 was accepted as
significant.
3. Results
The demographic data is summarised in Table 1.
3.1. Diagnostic Value of NfHSMI35. Serum NfHSMI35 levels
were significantly diﬀerent between the groups (F3,56 = 4.05,
P = 0.011). Serum NfHSMI35 levels were significantly higher
in patients with NMO (mean 0.79 ± 1.51 ng/mL) compared
to patients with CRION (0.13 ± 0.16 ng/mL, P = 0.007),
MSON (0.09±0.09, P = 0.008), and healthy controls (0.01±
0.02 ng/mL, P = 0.001, Figure 1).
From Figure 1 it is visible that the data was not normally
distributed and serum NfHSMI35 levels were particularly high
in two patients with NMO. For statistical rigorosity the
data was therefore also analysed on a categorical level. The
proportion of patients with NMO who had pathological
levels (7/9) was significant larger compared to controls (0/20,
P < 0.0001). Significance remained after the two NMO
patients with particular high serum NfHSMI35 levels were
removed (P < 0.0001).
Patients with MSON displayed the lowest levels of
NfHSMI35 out of the three optic neuritis subtypes, although
the diﬀerence between levels found in MSON and CRION
was markedly smaller than that between these two groups
andNMOon the one hand and healthy controls on the other.
3.2. Prognostic Value of NfHSMI35. Poor VA at onset (Figure 2)
and at the last follow-up visit, (Figure 3) was associated with
high serum NfHSMI35 levels in the pooled group analysis.
The NfHSMI35 level at the onset of optic neuritis correlated
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Figure 1: Serum NfHSMI35 levels are elevated in NMO compared
to control subjects and other inflammatory optic neuropathies.
Patients who were AQP4 seropositive are indicated in red.
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Figure 2: More severe loss of vision at onset is associated with
higher serum NfHSMI35 levels.
stronger with VA than did the NfHSMI35 level at the last
follow-up visit.
4. Discussion
To the best of our knowledge, this is the first published study
reporting the levels of NfHSMI35 in the serum of patients with
NMO and CRION. This study suggests that serum NfHSMI35
levels are of more prognostic then diagnostic value in the
setting of acute immune mediated optic neuropathies.
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Figure 3: High serum NfHSMI35 levels are associated with poor
visual outcome.
Our results are comparable to data on plasma NfHSMI35
levels in acute ON, where the median level of plasma
NfHSMI35 was found to be 0.17 ng/mL in patients with optic
neuritis and 0.005 ng/mL in control subjects [9].
Our findings support the concept that axonal loss follow-
ing optic neuritis is more extensive in patients with NMO
compared to MSON [6]. This is consistent with the clinical
observation of more server loss of visual function and retinal
nerve fibres in patients with NMO [20]. Interestingly, loss
of retinal nerve fibres as quantified by OCT was correlated
to serum pNfH levels in patients participating in the Optic
Neuritis Treatment Trial [11].
The correlation of high serum NfHSMI35 levels with poor
visual recovery in the present study further supports the
argument that axonal destruction with resulting retinal nerve
fibre loss may be to blame for the permanent visual deficit
after the attack. We speculate that longitudinal assessment
of blood NfHSMI35 levels may help to identify more severely
disabling events in relapsing conditions. It may be interesting
to find out whether or not blood NfHSMI35 were therefore
useful to improve prognostic accuracy in patients with AQP4
seropositive ON [17, 21] or in patients with NMO in whom
isolated peaks in serial antibody titres suggest active disease
[22].
A weakness of this study is that we did not have
systematic spinal cord MRI performed in all patients. This
may be relevant because high serum NfHSMI35 levels may
also be caused by axonal loss due to concomitant myelitis
in NMO which is clinically silent. In this context it is of
note that the highest serum NfHSMI35 levels were found in
an NMO patient who was also AQP4 seropositive. In total
4/5 (80%) of the AQP4 seropositive NMO patients had
serum NfHSMI35 levels above the highest value observed in
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the control cohort (0.05 ng/mL, horizontal dotted line in
Figures 2 and 3). This may require further investigation of
blood NfHSMI35 levels, particularly during an acute relapses
in NMO. Of note, removal of the two NMO patients with
particular high serum NfHSMI35 levels did not change the
statistical significance of the finding. It should be mentioned
that elevated serum NfHSMI35 levels can also be observed
in other neurological and nonneurological conditions such
as cardiac arrest [23], cardiac surgery [24], traumatic brain
injury [25], blast injury [26], subarachnoid haemorrhage
[27], stroke [28], endcarotidectomy [29], and motor neuron
disease [30, 31]. None of these were present in the patients
reported here. Some of these studies presented longitudinal
data which showed that serum NfHSMI35 levels peaked early
after acute injury. Therefore an important shortcoming of
our study was that the exact timing of sample acquisition in
relation from onset of ocular pain to venopuncture was not
collected systematically. This is an important point because
onset of ocular pain may precede onset of visual loss and
should be considered as time of onset in future studies. We
cannot exclude the possibility that patients presenting with
more severe loss of vision were recruited at an earlier time
point in their disease which could have skewed the data.
Another shortcoming of the study was that all patients
were recruited through a busy routine UK NHS clinic.
Therefore the timing of investigations and followup was
less systematic than what would have been desirable and
missing data limits the power of the present study. On
the other hand the data presented may be more reflective
for a hands on day-to-day neurological practise than a
randomised clinical trial setting. Likewise, a limitation of
the study is that assessment of low contrast VA was not
performed [32]. Because recovery of low-contrast VA and
colour vision following optic neuritis is poorer compared to
high contrast VA, correlation analyses of serum NfH levels
with these measures should be performed in future studies.
After this study was completed a number of method-
ological papers appeared in the literature showing diﬀerences
in the analytical sensitivity of a range of AQP4 tests [33].
Using some of the more sensitive tests may have increased
the proportion of AQP4 positive NMO cases in the present
study.
In conclusion, blood NfHSMI35 levels are of moderate
diagnostic and reasonable prognostic value in patients pre-
senting with an immune-mediated optic neuropathy.
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